The group’s principal activity is to provide therapeutic proteins and peptides. The group’s product lines include monoclonal antibodies, cancer vaccines, fusion proteins, hormones, cancer vaccines and anti-coagulants. The group operates from the United States and Europe.
Executive Information
Name
Title
Email
Jacques Van Kimmenaede
Pres. - Diosynth Biotechnology
N/A
George Koch
Chief Scientific Officer, Sr. Dir. - Customer Project Management
